BackgroundPatients with tuberculosis resistant to isoniazid but susceptible to rifampicin (Hr-Rs TB) remain a neglected demographic, despite a high disease burden and poor outcomes of these patients. The aim of this study was to investigate the characteristics of isoniazid-resistance-related mutations in Mycobacterium tuberculosis and resistance rates to drugs included in WHO-recommended regimens for Hr-Rs patients. MethodsMycobacterium tuberculosis isolates (n = 4922) obtained from national tuberculosis drug-resistance surveillance were subjected to whole-genome sequencing to identify Hr-Rs strains. The minimal inhibitory concentrations (MICs) were established for the Hr-Rs strains to determine the isoniazid resistance levels. We also identified drug-resistance-associated mutations for five drugs (fluoroquinolones, ethambutol, pyrazinamide, streptomycin, and amikacin) in the Hr-Rs strains. ResultsOf the 4922 strains, 384 (7.8%) were Hr-Rs. The subculture of seven strains failed, so 377 (98.2%) strains underwent phenotypic MIC testing. Among the 384 genotypic Hr-Rs strains, 242 (63.0%) contained the katG Ser315Thr substitution; 115 (29.9%) contained the -15C>T in the promoter region of the fabG1 gene; and 16 (4.2%) contained Ser315Asn in the katG gene. Of the 239 strains with the Ser315Thr substitution, 229 (95.8%) had MIC ≥ 2 µg/mL, and of the 114 strains with the -15C>T mutation, 103 (90.4%) had 0.25 µg/mL ≤ MIC ≤ 1 µg/mL. The genotypic resistance rates were 0.8% (3/384) for pyrazinamide, 2.3% (9/384) for ethambutol and fluoroquinolones; 39.6% (152/384) of the strains were resistant to streptomycin, but only 0.5% (2/384) of the strains were resistant to amikacin. ConclusionSer315Thr in katG was the predominant mutation conferring the Hr-Rs phenotype, followed by the fabG1 -15C>T mutation. The combination of rifampicin, pyrazinamide, ethambutol, and levofloxacin should be effective in the treatment of patients with Hr-Rs tuberculosis because the resistance rates for these drugs in China are low.